

Year (Movember Campaign Year)	Recipient and Institution	Program	Title	Award
2011	Shabbir Alibhai University Health Network	Movember Discovery 2013	A Phase II Rct And Economic Analysis Of Three Exercise Delivery Methods In Men With Prostate Cancer On ADT	\$195,796 CAD
2011	Xuesen Dong University of British Columbia	Movember Discovery 2013	Investigation Of The Progesterone Receptor In Prostate Cancer	\$200,000 CAD
2011	Alice Dragomir McGill University	Movember Discovery 2013	Healthcare Services Use, Clinical Outcomes And Economic Burden In Metastatic Castration-Resistant Prostate Cancer, Determinants And Trends: A Population Based Study	\$194,800 CAD
2011	Guy Faulkner University of Toronto	Movember Discovery 2013	RISEforTx: Testing The Feasibility Of A Web Application For Reducing Sitting During Treatment For Prostate Cancer	\$164,102 CAD
2011	Antonio Finelli University Health Network	Movember Discovery 2013	Active Surveillance For Low-Risk Prostate Cancer: A Population-Level Analysis Of Uptake, Practice Patterns And Barriers To Adoption	\$138,213 CAD
2011	Vincent Fradet Université Laval	Movember Discovery 2013	Development Of A Non-Invasive Inflammatory Profiling Test For Prostate Cancer	\$189,800 CAD
2011	Yves Fradet Université Laval	Movember Discovery 2013	Novel Immunotherapeutic Approaches For Localized Prostate Cancer	\$200,000 CAD
2011	Larry Goldenberg University of British Columbia	Movember Discovery 2013	Quality Of Life Outcomes In LHRH Treated Prostate Cancer Patients Treated With Supplementary Transdermal Estradiol. A Randomised Phase II Trial.	\$68,592.50 CAD
2011	Robert Hamilton University Health Network	Movember Discovery 2013	The Influence Of Genetic Variation On The Association Between Statin And Metformin Use And Prostate Cancer Risk: Towards Discovering Personalized Chemoprevention	\$200,000 CAD
2011	Fraser Hof University of Victoria	Movember Discovery 2013	Developing Small-Molecule Antagonists Of Chromobox 7 (CBX7) As Epigenetic Therapies For Aggressive Prostate Cancer	\$200,000 CAD
2011	Morley Hollenberg University of Calgary	Movember Discovery 2013	Kallikrein-PSA Signalling, Proteinase- Activated Receptors (PARs) And Prostate Cancer Development	\$197,836 CAD
2011	Khalid Al-Nedawi McMaster University	Movember Discovery 2013	The Role Of Microvesicular-Pten In Prostate Cancer: A Diagnostic Potential	\$194,000 CAD
2011	Subburaj Ilangumaran Université de Sherbrooke	Movember Discovery 2013	Role Of SOCS1 In Pathogenesis Of Prostate Cancer	\$200,000 CAD
2011	Thomas Kislinger University Health Network	Movember Discovery 2013	Integrated Genomics Of Tumor-Derived Exosomes For Prostate Cancer Diagnosis And Prognosis	\$200,000 CAD



Year (Movember Campaign Year)	Recipient and Institution	Program	Title	Award
2011	Eric Levesque Université Laval	Movember Discovery 2013	Estrogens And Prostate Cancer Progression	\$200,000 CAD
2011	Rongtuan Lin Jewish General Hospital	Movember Discovery 2013	Combination Oncolytic Virotherapy For The Treatment Of Prostate Cancer	\$200,000 CAD
2011	Stanley Liu Sunnybrook Research Institute	Movember Discovery 2013	MicroRNA And Prostate Cancer Radiation Response	\$200,000 CAD
2011	Salah Mahmud University of Manitoba	Movember Discovery 2013	Role Of Metformin And Other Hypoglycemic Medications In Prostate Cancer Prevention: A Population-Based Study	\$158,642 CAD
2011	Tak W. Mak University Health Network	Movember Discovery 2013	Investigation Of Predictive Biomarkers For First-In-Class Inhibitors Of Mitotic Kinases In Prostate Cancer	\$200,000 CAD
2011	Andrew Matthew University Health Network	Movember Discovery 2013	A Multicentre, Pilot Randomized Controlled Trial To Examine The Effects Of Prehabilitation On Functional Outcomes After Radical Prostatectomy	\$176,069 CAD
2011	Ur Metser University Health Network	Movember Discovery 2013	18F-FCH -PET/MR In High Risk Prostate Cancer: A Multiparametric Approach	\$199,558 CAD
2011	Linda Penn University Health Network	Movember Discovery 2013	Novel Window Of Opportunity Trial To Evaluate The Impact Of Statins To Oppose Prostate Cancer (Win-STOPca)	\$183,245 CAD
2011	Artem Cherkasov University of British Columbia	Movember Discovery 2013	Selective Targeting Of DNA-Binding Domain Of Androgen Receptor - A Novel Approach To Treat Castration-Resistant Prostate Cancer	\$200,000 CAD
2011	Fred Saad/Anne-Marie Mes- Masson Centre de recherche du Centre hospitalier de l'Université de Montréal	Movember Discovery 2013	Validation And Use Of A Microfluidic Platform To Test Prostate Cancer Response To Targeted Therapies	\$198,799 CAD
2011	Peter Siegel McGill University	Movember Discovery 2013	CCN3 As A Prognostic And Therapeutic Target In Prostate Cancer	\$197,000 CAD
2011	Hanadi Sleiman McGill University	Movember Discovery 2013	Conditional SiRNA Delivery To Prostate Cancer Cells Using DNA Cages	\$199,160 CAD
2011	Michel L. Tremblay McGill University	Movember Discovery 2013	Deciphering The Metabolic Role Of Protein Tyrosine Phosphatase 1B Towards Improving Prostate Cancer Prognosis And Therapeutics	\$198,496 CAD
2011	Nawaid Usmani University of Alberta	Movember Discovery 2013	A Validated Model To Predict The Risk Of Radiation Toxicity After Prostate Radiotherapy	\$193,665 CAD



Year (Movember Campaign Year)	Recipient and Institution	Program	Title	Award
2011	Geoffrey Wood University of Guelph	Movember Discovery 2013	Role Of Chronic Inflammation And Proteases In The Emergence Of Castration-Resistant Prostate Cancer	\$191,540 CAD
2011	Jian Hui Wu Jewish General Hospital	Movember Discovery 2013	Development Of Chemical Inhibitors Of ETS Oncoproteins For The Treatment Of Prostate Cancer	\$197,000 CAD
2011	George Yousef St Michael's Hospital	Movember Discovery 2013	A Non-Conventional Approach For Personalized Medicine In Prostate Cancer: Investigating The Role Of MiRNAs And Their Clinical Utility In Tumor Progression And Metastasis	\$192,000 CAD
2011	Colin Collins University of British Columbia	Movember Discovery 2013	Discovery And Functionalization Of RNA Editing In Prostate Cancer	\$184,446 CAD
2011	Roger Zemp University of Alberta	Movember Discovery 2013	Ultrasound-Stimulated Release Of Exosomes As Biomarkers	\$192,000 CAD
2011	Pieter Cullis University of British Columbia	Movember Discovery 2013	Targeted Lipid Nanoparticles For The Treatment Of Advanced Prostate Cancer	\$200,000 CAD
2011	Charles Cunningham Sunnybrook Research Institute	Movember Discovery 2013	Hyperpolarized Carbon-13 Imaging Of Advanced Metastatic Prostate Cancer	\$195,788 CAD
2011	Gregory Czarnota Sunnybrook Research Institute	Movember Discovery 2013	Prostate Cancer Microbubble Antivascular Enhancement Of Radiation	\$198,600 CAD
2011	Robert Day Université de Sherbrooke	Movember Discovery 2013	Beyond PSA: PACE4 As A Candidate Biomarker For Prostate Cancer	\$73,500 CAD
2011	Gregory Dekaban University of Western Ontario	Movember Discovery 2013	Dendritic Cell-Based Prostate Cancer Vaccine: Development Of In Vivo Dendritic Cell Migration By Cellular MRI In Humans	\$142,702 CAD
2012	Khalid Al-Nedawi McMaster University	Movember Discovery 2014	Regulation of Androgen receptor through microvesicles	\$200,000 CAD
2012	Bharati Bapat Lunenfeld-Tanenbaum Research Institute	Movember Discovery 2014	Deciphering DNA Methylome in Metastatic Prostate Cancer	\$185,900 CAD
2012	Peter Black University of British Columbia	Movember Discovery 2014	Circulating Tumour Cells for Risk Stratification in Men with Localized Prostate Cancer	\$182,800 CAD
2012	Warren Chan University of Toronto	Movember Discovery 2014	Designing controlled release DNA-based drug delivery systems	\$186,991 CAD
2012	Kim Chi BC Cancer Agency - Vancouver	Movember Discovery 2014	Genomic Profiling of Circulating Tumour DNA (ctDNA) as a Predictive Biomarker for Patients with Castration Resistant Prostate Cancer (CRPC)	\$99,650 CAD



Year (Movember Campaign Year)	Recipient and Institution	Program	Title	Award
2012	Imed Gallouzi McGill University	Movember Discovery 2014	Elucidation of regulatory posttranscriptional mechanisms modulating STAT3 expression during prostate cancer-induced cachexia (muscle atrophy)	\$194,000 CAD
2012	Fernand Gobeil Université de Sherbrooke	Movember Discovery 2014	Inducible kinin B1 receptors as prostate cancer theranostic targets	\$200,000 CAD
2012	SM Mansour Haeryfar University of Western Ontario	Movember Discovery 2014	NKT Cell-based Adjuvant Immunotherapy of Prostate Cancer	\$188,068 CAD
2012	Gerald Krystal BC Cancer Agency – Vancouver	Movember Discovery 2014	Generation of Mesenchymal Stromal Cells Infected with Oncolytic Herpes Viruses Expressing Immune Modulators to Treat Prostate Cancer	\$200,000 CAD
2012	Shawn Li University of Western Ontario	Movember Discovery 2014	Therapeutic potential of targeting SET7/9 induced methylation of DNA-PKcs in androgen-resistant prostate cancer	\$187,000 CAD
2012	Andrew Loblaw Sunnybrook Health Sciences Centre	Movember Discovery 2014	Single fraction HDR prostatic boost in the context of pelvic lymph node SABR (5 fractions) for high risk prostate cancer	\$159,650 CAD
2012	Rodney Breau Ottawa Hospital Research Institute	Movember Discovery 2014	Improving quality of prostate cancer surgery by providing performance feedback to surgeons: A pilot study	\$194,777 CAD
2012	Andrew Matthew University Health Network	Movember Discovery 2014	A Randomized Trial of Conventional versus Advanced Pelvic Floor Exercises to Treat Urinary Incontinence Following Radical Prostatectomy	\$158,291 CAD
2012	Donald Poirier Université Laval	Movember Discovery 2014	An outstanding accumulation of a 17-beta-hydroxysteroid dehydrogenase type 3 (17b-HSD3) inhibitor in prostate cancer tumor open the door to a specific treatment and imaging of prostate cancer using a radiolabeled 17b-HSD3 inhibitor	\$199,944 CAD
2012	Gurmit Singh McMaster University	Movember Discovery 2014	Prostate cancer-induced Depression	\$198,685 CAD
2012	Jose Teodoro McGill University	Movember Discovery 2014	Role of the Pro-Renin Receptor in the progression and diagnosis of Prostate Cancer	\$200,000 CAD
2012	Yuzhuo Wang University of British Columbia	Movember Discovery 2014	Identification of genes involved in development and progression of neuroendocrine prostate cancer	\$200,000 CAD
2012	Xiao Yu (Shirley) Wu University of Toronto	Movember Discovery 2014	Hypoxia-modulating nanoparticles for enhancing radiation response of inoperable advanced prostate cancer	\$200,000 CAD



Year (Movember Campaign Year)	Recipient and Institution	Program	Title	Award
2012	Alexandre Zlotta Mount Sinai Hospital	Movember Discovery 2014	Advancing Precision Medicine for Prostate Cancer Through Transcriptomics	\$200,000 CAD
2012	Vincent Fradet Université Laval	Movember Discovery 2014	Epigenomic control of prostatic inflammation	\$198,000 CAD
2012	Stephane Gobeil Université Laval	Movember Discovery 2014	Identification of new metastasis suppressor genes in prostate cancer	\$199,772 CAD
2012	Hon Leong University of Western Ontario	Movember Discovery 2014	Developing a Liquid Biopsy Format of Gleason Scoring for Prostate Cancer Prognostication	\$180,014 CAD
2012	Salah Mahmud University of Manitoba	Movember Discovery 2014	The effect of antipsychotic medications on the incidence and aggressiveness of prostate cancer: a population based study	\$153,462 CAD
2012	Naomi Matsuura University of Toronto	Movember Discovery 2014	Nanoscale oxygen transport carriers for radiosensitization of prostate tumours	\$197,656 CAD
2012	Rithwik Ramachandran University of Western Ontario	Movember Discovery 2014	Molecular regulation of TRPM8 in prostate cancer	\$199,735 CAD
2012	Juan Ausio University of Victoria	Movember Discovery 2014	Examining the interplay between H2A.Z and EZH2 in androgen receptor dependent and independent signalling in Prostate cancer	\$185,842 CAD
2013	Cheryl Helgason BC Cancer Agency - Vancouver	Movember Discovery 2015	Functional analysis of PCAT18	\$89,378 CAD
2013	Tommy Alain Children's Hospital of Eastern Ontario Research institute	Movember Discovery 2015	Deciphering the fundamental implications of LARP1 in mTORC1-addicted prostate cancer	\$190,000 CAD
2013	Michel L Tremblay McGill University	Movember Discovery 2015	Characterization and prognostic potential of the prostate cancer genetic-susceptibility amplicon on chromosome 20q13 during tumour progression	\$197,322 CAD
2013	Roger Zemp University of Alberta	Movember Discovery 2015	Nano- and imaging platforms for prostate cancer personalized medicine	\$200,000 CAD
2013	Dominique Trudel Centre de recherche du Centre hospitalier de l'Université de Montréal	Movember Discovery 2015	Adaptation of inelastic scattering detection technology for label-free molecular imaging to improve the reliability of prostatic biopsies	\$199,000 CAD



Year (Movember Campaign Year)	Recipient and Institution	Program	Title	Award
2013	Alexander Wyatt University of British Columbia	Movember Discovery 2015	Circulating biomarkers of cabazitaxel response and progression in castration-resistant prostate cancer	\$197,000 CAD
2013	Gang Zheng University Health Network	Movember Discovery 2015	Harnessing the microbubble to nanoparticle conversion for photodynamic therapy of recurrent prostate cancer	\$200,000 CAD
2013	Jian Hui Wu Lady Davis Institute	Movember Discovery 2015	Development of human STING agonists for prostate cancer immunotherapy	\$200,000 CAD
2013	Julian Lum BC Cancer Agency - Vancouver	Movember Discovery 2015	Exploiting the immune effects of androgen deprivation and radiotherapy for the treatment of high-risk prostate cancer	\$188,500 CAD
2013	Robert Hamilton University Health Network	Movember Discovery 2015	Molecular characterization and behavior of tumours arising in patients taking 5-alpha reductase inhibitors	\$199,961 CAD
2013	Alice Dragomir Research Institute of the McGill University Health Centre	Movember Discovery 2015	Development of a clinical and economic model for evaluating new tests or strategies of diagnosis, treatment and management of prostate cancer	\$181,515 CAD
2013	Stanley Liu Sunnybrook Research Institute	Movember Discovery 2015	MicroRNA as mediators of radioresistance in prostate cancer patients	\$87,567 CAD
2013	Ivan Topisirovic Lady Davis Institute	Movember Discovery 2015	Resolving gene expression landscapes in prostate cancer through ex-vivo modelling of stromal-epithelial cross-talk	\$87,567 CAD
2013	Franco Vizeacoumar University of Saskatchewan	Movember Discovery 2015	Validating synthetic dosage lethal interactions of PLK1 in androgen-insensitive prostate cancer cells.	\$87,567 CAD
2014	Housheng He University Health Network	Movember Discovery 2016	Identifying functional long noncoding RNAs in prostate cancer	\$198,000 CAD
2014	Yuzhuo Wang University of British Columbia	Movember Discovery 2016	Identification of potential therapeutic targets for AR pathway inhibitor-resistant prostate cancer	\$200,000 CAD
2014	Frank Wuest University of Alberta	Movember Discovery 2016	Silicon-Fluorine-PSMA: A winning team for early prostate cancer detection	\$200,000 CAD
2013	Honshen Ma University of British Columbia	Movember Discovery 2016	Investigating Castrate Resistant Prostate Cancer Through Transcriptome Profiling of Single CTCs	\$200,000 CAD
2013	Roseline Godbout University of Alberta	Movember Discovery 2016	Role of a Novel Fatty Acid Binding Protein (FABP12) in Prostate Cancer Lipid Metabolism and Progression	\$199,820 CAD
2014	Vincent Fradet Université Laval	Movember Discovery 2016	Role of Gut Microbiota on anti-Inflammatory effect of Omega-3 in Prostate Cancer	\$197,944 CAD



Year (Movember Campaign Year)	Recipient and Institution	Program	Title	Award
2014	Septimu Salcudean University of British Columbia	Movember Discovery 2016	Quantitative multimodal imaging of prostate cancer	\$184,108 CAD
2014	Richard Baverstock University of Calgary	Movember Discovery 2016	Measuring the relationship between overactive bladder symptoms and prostate cancer treatment: is it bi-directional?	\$186,904 CAD
2014	Jian Hui Wu Lady Davis Institute	Movember Discovery 2016	Development of novel GATA2 inhibitors for breaking the critical AR-GATA2 feedback loop in castration-resistant prostate cancer	\$191,000 CAD
2014	Madhuri Koti Queen's University	Movember Discovery 2016	PTEN regulated interferon pathways as novel therapeutic targets in prostate cancer	\$198,000 CAD
2014	Paul Toren Université Laval	Movember Discovery 2016	The role of serum steroids in the development of castrate resistant prostate cancer: a secondary analysis of the PR.7 trial	\$115,192 CAD
2014	Shawn Li Western University	Movember Discovery 2016	Global and quantitative kinomic and phosphoproteomic analysis of advanced prostate cancer to enable effective treatment	\$200,000 CAD
2015	Stanley Liu Sunnybrook Research Institute	Movember Discovery 2017	Interrogating radioresistance in prostate cancer: leveraging combined genomic and proteomic analyses	\$200,000 CAD
2015	Greg Stanisz Sunnybrook Research Institute	Movember Discovery 2017	Chemical Exchange Saturation Transfer MRI as a Biomarker of Tumour Response to Radiation Treatment	\$199,999 CAD
2015	Caroline Pukall Queen's University	Movember Discovery 2017	Healthcare experiences and health-related quality of life in LGBTQ+ individuals with localized prostate cancer: A longitudinal, mixed-methods study with a special focus on psychosexual outcomes	\$199,583 CAD
2015	Theodorus van der Kwast University Health Network	Movember Discovery 2017	Molecular-genetic characterization of a cancer field effect associated with intraductal carcinoma of the prostate	\$200,000 CAD
2015	Jose Teodoro McGill University	Movember Discovery 2017	The vaculoar ATPase complex as a therapeutic target in prostate cancer	\$200,000 CAD
2015	Alexander Wyatt University of British Columbia	Movember Discovery 2017	Genomic truncation of the Androgen Receptor in poor-prognosis castration-resistant prostate cancer	\$200,000 CAD
2015	Christopher Mueller Queen's University	Movember Discovery 2017	Markers of poor outcome in castrate resistant prostate cancer	\$200,000 CAD
2015	John Ronald University of Western Ontario	Movember Discovery 2017	Tumour-Activatable Minicircles: Novel Transcription-Based Blood/Urine Assays for Assessing Prostate Cancer Aggressiveness	\$200,000 CAD



Year (Movember Campaign Year)	Recipient and Institution	Program	Title	Award
2015	Alison Allan University of Western Ontario	Movember Discovery 2017	Dynamic influence of the epithelial-to- mesenchymal transition on circulating tumor cell (CTC) generation, phenotype, and disease progression in prostate cancer	\$199,282 CAD
2014/2015	Neil Fleshner University Health Network	Movember Discovery 2017	Assessing Positive Margins at Radical Prostatectomy Using Real-Time High Resolution Prostate-Specific Membrane Antigen-Based Gamma Imaging of the Prostate Bed	\$192,482 CAD
2015	Lori Brotto University of British Columbia	Movember Discovery 2017	Innovations in the treatment of sexual dysfunction and couple intimacy after prostate cancer: A randomized trial of mindfulness versus cognitive behavioural therapy	\$187,256 CAD
2015	Richard Austin McMaster University	Movember Discovery 2017	Disrupting the interaction of anti-GRP78 autoantibodies to tumour cell surface GRP78 as novel therapeutic approach for the treatment of prostate cancer.	\$193,700 CAD